Thrombomodulin ameliorates transforming growth factor- β1–mediated chronic kidney disease via the G-protein coupled receptor 15/Akt signal pathway

Kidney fibrosis is the common consequence of chronic kidney diseases that inexorably progresses to end-stage kidney disease with organ failure treatable only with replacement therapy. Since transforming growth factor- β1 is the main player in the pathogenesis of kidney fibrosis, we posed the hypothesis that recombinant thrombomodulin can ameliorate transforming growth factor-β1–mediated progressive kidney fibrosis and failure. To interrogate our hypothesis, we generated a novel glomerulus-specific human trans forming growth factor-β1 transgenic mouse to evaluate the therapeutic effect of recombinant thrombomodulin.

Source: Kidney International - October 13, 2020 Category: Urology & Nephrology Authors: Atsuro Takeshita, Taro Yasuma, Kota Nishihama, Corina N. D ’Alessandro-Gabazza, Masaaki Toda, Toshiaki Totoki, Yuko Okano, Akihiro Uchida, Ryo Inoue, Liqiang Qin, Shujie Wang, Valeria Fridman D’Alessandro, Tetsu Kobayashi, Yoshiyuki Takei, Akira Mizog Tags: Basic Research Source Type: research